HomeCompareENTO vs BTI

ENTO vs BTI: Dividend Comparison 2026

ENTO yields 70.18% · BTI yields 5.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ENTO wins by $1.02M in total portfolio value
10 years
ENTO
ENTO
● Live price
70.18%
Share price
$2.85
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.06M
Annual income
$278,697.01
Full ENTO calculator →
BTI
BTI
● Live price
5.38%
Share price
$58.47
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.7K
Annual income
$2,786.64
Full BTI calculator →

Portfolio growth — ENTO vs BTI

📍 ENTO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodENTOBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ENTO + BTI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ENTO pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ENTO
Annual income on $10K today (after 15% tax)
$5,964.91/yr
After 10yr DRIP, annual income (after tax)
$236,892.46/yr
BTI
Annual income on $10K today (after 15% tax)
$457.40/yr
After 10yr DRIP, annual income (after tax)
$2,368.64/yr
At 15% tax rate, ENTO beats the other by $234,523.81/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ENTO + BTI for your $10,000?

ENTO: 50%BTI: 50%
100% BTI50/50100% ENTO
Portfolio after 10yr
$548.8K
Annual income
$140,741.83/yr
Blended yield
25.64%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

ENTO
No analyst data
Altman Z
-1.6
Piotroski
2/9
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.6% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ENTO buys
0
BTI buys
0
No recent congressional trades found for ENTO or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricENTOBTI
Forward yield70.18%5.38%
Annual dividend / share$2.00$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3%
Portfolio after 10y$1.06M$37.7K
Annual income after 10y$278,697.01$2,786.64
Total dividends collected$903.3K$14.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: ENTO vs BTI ($10,000, DRIP)

YearENTO PortfolioENTO Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$17,718$7,017.54$11,299$598.92+$6.4KENTO
2$30,578$11,619.97$12,794$703.91+$17.8KENTO
3$51,460$18,742.30$14,518$829.07+$36.9KENTO
4$84,541$29,478.65$16,513$978.64+$68.0KENTO
5$135,720$45,260.50$18,827$1,157.84+$116.9KENTO
6$213,126$67,906.19$21,518$1,373.12+$191.6KENTO
7$327,705$99,659.70$24,657$1,632.46+$303.0KENTO
8$493,857$143,212.72$28,329$1,945.74+$465.5KENTO
9$730,132$201,704.73$32,637$2,325.33+$697.5KENTO
10$1,059,938$278,697.01$37,708$2,786.64+$1.02MENTO

ENTO vs BTI: Complete Analysis 2026

ENTOStock

First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides; biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; capeserod, a selective 5-HT4 receptor partial agonist to treat gastroparesis; and niclosamide, an oral small molecule with anti-inflammatory properties for patients with inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease. It is also developing CypCel, a disease management tool for monitoring the intestinal health of recovering celiac disease patients. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.

Full ENTO Calculator →

BTIConsumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this ENTO vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ENTO vs SCHDENTO vs JEPIENTO vs OENTO vs KOENTO vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.